37.70

4.35% -1.715

After Hours: 37.71 0.005 +0.01%

Praxis Precision Medicines Inc (PRAX)

Overview News Price History Option Chain Financials Discussions Forecast

Praxis Precision Medicines Inc stock is traded at $37.70, with a volume of 496.51K. It is down -4.35% in the last 24 hours and down -22.19% over the past month. Praxis Precision Medicines Inc is a clinical-stage biopharmaceutical company. The firm is engaged in translating genetic insights into the development of therapies for patients affected by central nervous system disorders characterized by a neuronal excitation-inhibition imbalance. The company has generated three clinical-stage product candidates, ulixacaltamide (formerly known as PRAX-944), vormatrigine (formerly known as PRAX-628), and relutrigine (formerly known as PRAX-562), as well as PRAX-020 which has been in-licensed by UCB Biopharma SRL, or UCB.

Previous Close:

$39.42

Open:

$39.08

24h Volume:

496.51K

Relative Volume:

1.17

Market Cap:

$793.53M

Revenue:

$1.77M

Net Income/Loss:

$-123.74M

P/E Ratio:

-4.1118

EPS:

-9.17

Net Cash Flow:

$-95.21M

1W Performance:

-19.52%

1M Performance:

-22.19%

6M Performance:

-2.24%

1Y Performance:

-35.77%

1-Day Range:

$37.64

$39.27

1-Week Range:

$37.19

$43.15

52-Week Range:

$26.70

$91.83

Praxis Precision Medicines Inc Stock (PRAX) Company Profile

Name

Praxis Precision Medicines Inc

Sector

Healthcare (1152)

Industry

Biotechnology (648)

Phone

617-300-8460

Address

99 HIGH STREET, 30TH FLOOR, BOSTON

Employee

Twitter

Next Earnings Date

2024-11-06

Latest SEC Filings

PRAX's Discussions on Twitter

Compare PRAX with other stocks

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
PRAX Praxis Precision Medicines Inc	37.70	846.82M	1.77M	-123.74M	-95.21M	-9.17
VRTX Vertex Pharmaceuticals Inc	394.53	99.62B	11.39B	3.64B	3.50B	13.99
ALNY Alnylam Pharmaceuticals Inc	465.89	61.52B	2.46B	-319.09M	-52.09M	-2.47
REGN Regeneron Pharmaceuticals Inc	560.00	58.91B	14.21B	4.46B	3.56B	39.68
ARGX Argen X Se Adr	756.38	46.69B	3.06B	1.28B	447.35M	21.30
ONC Beone Medicines Ltd Adr	324.34	34.54B	3.81B	-644.79M	-669.77M	-6.24

Praxis Precision Medicines Inc Stock (PRAX) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Jun-02-25	Resumed	Oppenheimer	Outperform
May-07-25	Initiated	Chardan Capital Markets	Buy
Mar-03-25	Reiterated	H.C. Wainwright	Buy
Feb-11-25	Initiated	Deutsche Bank	Buy
Aug-05-24	Initiated	Oppenheimer	Outperform
Jun-24-24	Initiated	Needham	Buy
Jun-18-24	Initiated	Guggenheim	Buy
May-01-24	Initiated	Robert W. Baird	Outperform
Sep-19-23	Initiated	Truist	Buy
Jun-06-22	Downgrade	Wedbush	Outperform → Neutral
Dec-16-21	Initiated	H.C. Wainwright	Buy
Aug-26-21	Initiated	BofA Securities	Buy
Apr-26-21	Initiated	William Blair	Outperform
Nov-11-20	Initiated	Wedbush	Outperform
Nov-10-20	Initiated	Cowen	Outperform
Nov-10-20	Initiated	Evercore ISI	Outperform
Nov-10-20	Initiated	Piper Sandler	Overweight

View All

Praxis Precision Medicines Inc Stock (PRAX) Latest News

02:57 AM

Praxis Precision Medicines, Inc. (NASDAQ:PRAX) Given Average Rating of "Moderate Buy" by Analysts - MarketBeat

02:57 AM

Sep 11, 2025

Invesco Ltd. Has $442,000 Stock Position in Praxis Precision Medicines, Inc. $PRAX - MarketBeat

Sep 11, 2025

Praxis Precision Medicines (NASDAQ:PRAX) Stock Price Down 5.9%What's Next? - MarketBeat

Sep 11, 2025

Alyeska Investment Group L.P. Sells 76,788 Shares of Praxis Precision Medicines, Inc. $PRAX - MarketBeat

Sep 11, 2025

Equities Analysts Offer Predictions for PRAX Q3 Earnings - MarketBeat

Sep 11, 2025

Sep 10, 2025

Praxis Precision Medicines (NASDAQ:PRAX) Shares Gap DownHere's What Happened - MarketBeat

Sep 10, 2025